NCT02116205View on ClinicalTrials.gov

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

July 9, 2014

Primary Completion Date

December 7, 2016

Study Completion Date

July 31, 2017

Conditions
Hemorrhagic Fever With Renal Syndrome
Interventions
BIOLOGICAL

HTNV/PUUV DNA vaccine

HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)

BIOLOGICAL

Placebo

0.9% sodium chloride

DEVICE

TriGrid Delivery System (TDS)

The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses

Trial Locations (1)

20910

Walter Reed Army Institute of Research Clinical Trials Center, Silver Spring

Sponsors
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Ichor Medical Systems Incorporated

INDUSTRY

collaborator

United States Army Medical Materiel Development Activity

FED

collaborator

US Army Medical Research Institute of Infectious Diseases

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT02116205 - Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever | Biotech Hunter | Biotech Hunter